G. Brusselle (Ghent, Belgium), A. Menzies-Gow (London, United Kingdom)
Late Breaking Abstract - Open-label trial of budesonide/formoterol reliever therapy in mild asthma
J. Hardy (Wellington, New Zealand), C. Baggott (Wellington, New Zealand), J. Fingleton (Wellington, New Zealand), H. Reddel (Sydney, Australia), R. Hancox (Hamilton, New Zealand), M. Harwood (Auckland, New Zealand), A. Corin (Tauranga, New Zealand), J. Sparks (Wellington, New Zealand), D. Hall (Wellington, New Zealand), D. Sabbagh (Wellington, New Zealand), S. Mane (Wellington, New Zealand), S. Vohlidkova (Wellington, New Zealand), J. Martindale (Wellington, New Zealand), M. Williams (Wellington, New Zealand), P. Shirtcliffe (Wellington, New Zealand), M. Holliday (Wellington, New Zealand), M. Weatherall (Wellington, New Zealand), R. Beasley (Wellington, New Zealand)
|     |
Late Breaking Abstract - Identifying and addressing patient beliefs driving SABA use and over-reliance
R. Horne (London, United Kingdom), A. Chan (London, United Kingdom), J. Haughney (Aberdeen, United Kingdom), J. Correia De Sousa (Braga, Portugal), S. Williams (Westhill, Scotland, United Kingdom), A. Kaplan (Toronton, Canada)
| |
Late Breaking Abstract - Overuse of oral corticosteroids in asthma – modifiable factors and potential role of biologics
K. Eger (Amsterdam, Netherlands), M. Amelink (Amsterdam, Netherlands), P. Hekking (Amsterdam, Netherlands), E. Bel (Amsterdam, Netherlands)
| |
Clinical and histological impact of omalizumab in oral corticosteroid-dependent severe allergic asthma
C. Domingo Ribas (Sabadell, Spain), F. González-Barcala (Santiago de Compostela, Spain), F. Garcia (Barcelona, Spain), D. Moriña (Barcelona, Spain), F. Salgado (santiago de Compostela, Spain), V. Marco (Barcelona, Spain), J. Oliva (Sabadell, Spain), R. Mirapeix (Sabadell, Spain)
| |
Phase 1 evaluation of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, a potent and selective blocker of IL-4Ra
I. Bruns (Boston, United States of America), M. Fitzgerald (Boston, United States of America), K. Pardali (Gotherburg, Sweden), G. Philip (Gotherburg, Sweden), K. David (Gotherburg, Sweden), A. Lena (Gotherburg, Sweden), J. Fanyi (Gotherburg, Sweden), L. Jason (Melbourne, Australia), C. David (Cambridge, United Kingdom)
| |
Baseline predictors of being exacerbation-free during 2 years of benralizumab treatment
J. Upham (Brisbane, Australia), D. Jackson (London, United Kingdom), P. Barker (Gaithersburg, United States of America), P. Newbold (Gaithersburg, United States of America), W. Cook (Gaithersburg, United States of America)
| |
Azithromycin add-on therapy reduces airway inflammation and extracellular DNA: An AMAZES sub-study.
J. Simpson (Newcastle, Australia), D. Barker (Newcastle, Australia), I. Yang (Brisbane, Australia), J. Upham (Brisbane, Australia), P. Reynolds (Adelaide, Australia), S. Hodge (Adelaide, Australia), A. James (Perth, Australia), C. Jenkins (Sydney, Australia), M. Peters (Sydney, Australia), G. Marks (Sydney, Australia), M. Baraket (Sydney, Australia), P. Gibson (Newcastle, Australia)
| |
Effect of high extrafine strength (HS) ICS-containing triple therapy on exacerbations in patients with severe asthma and persistent airflow limitation: Post-hoc analysis of the TRIGGER study
W. Canonica (Milan, Italy), J. Virchow (Rostock, Germany), D. Singh (Manchester, United Kingdom), M. Kots (Parma, Italy), F. Zuccaro (Parma, Italy), A. Vele (Parma, Italy), G. Georges (Parma, Italy), S. Petruzzelli (Parma, Italy)
| |